To evaluate the performance of the engineered destabilized ARE 3’UTR of ERBB2 in controlling the ERBB2 transcript and downstream kinases in comparison to ShRNAi and genome-scale CRISPR, we analyzed the publicly available database for ShRNAi and CRISPR (Vizeacoumar et al., 2013; Hart et al., 2015; Martin et al., 2017) in HCT116, a colorectal carcinoma cell, an ERBB2-expressing cancer. The gene discussed is ERBB2; the disease is colorectal carcinoma.